Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 15:00 save search
Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
Published: 2022-06-03 (Crawled : 15:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.16%
H: 3.3%
C: 1.27%
solutions biosimilar positive phase 3
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
rinvoq trials positive results phase 3
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial china positive results phase 3
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
Published: 2022-02-11 (Crawled : 15:00) - biospace.com/
OCUL | News | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
glaucoma ocular trial presentation phase 1 phase 2 phase 3
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 4.98%
H: 1.33%
C: -2.74%
health cardio liver cardiovascular positive topline phase 3
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: 3.81%
H: 11.07%
C: -3.92%
skinte fda fda approval skin approval phase 3
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
Published: 2022-01-05 (Crawled : 15:00) - biospace.com/
OTLC | $0.042 -44.63% 100K
|
Manufacturing
|
| O: 0.0%
H: 4.12%
C: -0.88%
trial phase 1 phase 2 phase 3
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking CessationTopline ORCA-2 Results Expected in Q2 2022
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial results topline life science phase 3
Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -0.56%
H: 3.56%
C: 3.18%
covid-19 als biopharma covid positive phase 3
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
trial phase 1 phase 2 phase 3
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
Published: 2021-12-02 (Crawled : 15:00) - biospace.com/
DCTH | $4.87 3.73% 3.59% 300K
|
Health Technology
|
| O: -4.43%
H: 1.29%
C: -1.62%
ocular liver trial trial results positive results phase 3 hepzato
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 5.86%
H: 2.93%
C: -4.89%
chronic refractory gout bioscience phase 3 enroll sel-212
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
HRMY | $29.42 1.34% 1.33% 390K
|
Health Technology
|
| O: 5.34%
H: 4.4%
C: -1.0%
treatment trial bioscience phase 3
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
Published: 2021-11-11 (Crawled : 15:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.11%
H: 0.41%
C: 0.12%
heart phase 3
Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 1.63%
H: 3.5%
C: 2.92%
hepatitis biopharma phase 3 lonafarnib enroll
Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence® Oral Leuprolide
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
SWKH | $17.52 1.04% 1.03% 7.7K
|
Miscellaneous
|
| O: -0.76%
H: 5.82%
C: 3.62%
biopharma phase 1 trial phase 3 phase 2
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus- Phase 1/1b clinical trial will assess the safety and immunogenicity of IVX-121 in healthy adults, including older adults -
Published: 2021-09-09 (Crawled : 15:00) - biospace.com/
ICVX | $15.31 -0.65% 9.3M
|
|
| O: -0.28%
H: 2.89%
C: -0.2%
phase 1 respiratory vaccine trial phase 2 phase 3 order
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress
Published: 2021-08-31 (Crawled : 15:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.25%
H: 19.31%
C: 13.2%
presentation lung cancer europe cancer phase 3 plinabulin
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
Published: 2021-08-20 (Crawled : 15:00) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 0.32%
H: 11.82%
C: 6.71%
alcohol use disorder treatment phase 3 trial enroll
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
Published: 2021-07-19 (Crawled : 15:00) - prnewswire.com
BMRN S | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.